Literature DB >> 30098962

Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial.

Kavita Sharma1, Joban Vaishnav2, Rohan Kalathiya2, Jiun-Ruey Hu2, John Miller2, Nishant Shah2, Terence Hill2, Michelle Sharp2, Allison Tsao2, Kevin M Alexander2, Richa Gupta2, Kristina Montemayor2, Lara Kovell2, Jessica E Chasler2, Yizhen J Lee2, Derek M Fine3, David A Kass2, Robert G Weiss2, David R Thiemann2, Chiadi E Ndumele2, Steven P Schulman2, Stuart D Russell2.   

Abstract

OBJECTIVES: This study sought to compare a continuous infusion diuretic strategy versus an intermittent bolus diuretic strategy, with the addition of low-dose dopamine (3 μg/kg/min) in the treatment of hospitalized patients with heart failure with preserved ejection fraction (HFpEF).
BACKGROUND: HFpEF patients are susceptible to development of worsening renal function (WRF) when hospitalized with acute heart failure; however, inpatient treatment strategies to achieve safe and effective diuresis in HFpEF patients have not been studied to date.
METHODS: In a prospective, randomized, clinical trial, 90 HFpEF patients hospitalized with acute heart failure were randomized within 24 h of admission to 1 of 4 treatments: 1) intravenous bolus furosemide administered every 12 h; 2) continuous infusion furosemide; 3) intermittent bolus furosemide with low-dose dopamine; and 4) continuous infusion furosemide with low-dose dopamine. The primary endpoint was percent change in creatinine from baseline to 72 h. Linear and logistic regression analyses with tests for interactions between diuretic and dopamine strategies were performed.
RESULTS: Compared to intermittent bolus strategy, the continuous infusion strategy was associated with higher percent increase in creatinine (continuous infusion: 16.01%; 95% confidence interval [CI]: 8.58% to 23.45% vs. intermittent bolus: 4.62%; 95% CI: -1.15% to 10.39%; p = 0.02). Low-dose dopamine had no significant effect on percent change in creatinine (low-dose dopamine: 12.79%; 95% CI: 5.66% to 19.92%, vs. no-dopamine: 8.03%; 95% CI: 1.44% to 14.62%; p = 0.33). Continuous infusion was also associated with greater risk of WRF than intermittent bolus (odds ratio [OR]: 4.32; 95% CI: 1.26 to 14.74; p = 0.02); no differences in WRF risk were seen with low-dose dopamine. No significant interaction was seen between diuretic strategy and low-dose dopamine (p > 0.10).
CONCLUSIONS: In HFpEF patients hospitalized with acute heart failure, low-dose dopamine had no significant impact on renal function, and a continuous infusion diuretic strategy was associated with renal impairment. (Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction [ROPA-DOP]; NCT01901809).
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  acute decompensated heart failure; diuresis; dopamine; heart failure with preserved ejection fraction; worsening renal function

Mesh:

Substances:

Year:  2018        PMID: 30098962     DOI: 10.1016/j.jchf.2018.04.008

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  11 in total

1.  Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction.

Authors:  Yogesh N V Reddy; Masaru Obokata; Jeffrey M Testani; G Michael Felker; W H Wilson Tang; Omar F Abou-Ezzeddine; Jie-Lena Sun; Hrishikesh Chakrabothy; Steven McNulty; Sanjiv J Shah; Gregory D Lewis; Lynne W Stevenson; Margaret M Redfield; Barry A Borlaug
Journal:  J Card Fail       Date:  2019-10-13       Impact factor: 5.712

Review 2.  Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity.

Authors:  Akanksha Agrawal; Mario Naranjo; Napatt Kanjanahattakij; Janani Rangaswami; Shuchita Gupta
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 3.  Loop diuretic resistance complicating acute heart failure.

Authors:  Zachary L Cox; Jeffrey M Testani
Journal:  Heart Fail Rev       Date:  2020-01       Impact factor: 4.214

Review 4.  Furosemide as a functional marker of acute kidney injury in ICU patients: a new role for an old drug.

Authors:  Filippo Mariano; Alberto Mella; Marco Vincenti; Luigi Biancone
Journal:  J Nephrol       Date:  2019-05-14       Impact factor: 3.902

Review 5.  Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome.

Authors:  Zachary L Cox; Veena S Rao; Jeffrey M Testani
Journal:  Kidney360       Date:  2022-03-01

6.  Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis.

Authors:  Virginia S Hahn; Lisa R Yanek; Joban Vaishnav; Wendy Ying; Dhananjay Vaidya; Yi Zhen Joan Lee; Sarah J Riley; Vinita Subramanya; Emily E Brown; C Danielle Hopkins; Sandra Ononogbu; Kira Perzel Mandell; Marc K Halushka; Charles Steenbergen; Avi Z Rosenberg; Ryan J Tedford; Daniel P Judge; Sanjiv J Shah; Stuart D Russell; David A Kass; Kavita Sharma
Journal:  JACC Heart Fail       Date:  2020-07-08       Impact factor: 12.035

Review 7.  Cellular and molecular pathobiology of heart failure with preserved ejection fraction.

Authors:  Sumita Mishra; David A Kass
Journal:  Nat Rev Cardiol       Date:  2021-01-11       Impact factor: 49.421

Review 8.  Insights of Worsening Renal Function in Type 1 Cardiorenal Syndrome: From the Pathogenesis, Biomarkers to Treatment.

Authors:  Kang Fu; Yue Hu; Hui Zhang; Chen Wang; Zongwei Lin; Huixia Lu; Xiaoping Ji
Journal:  Front Cardiovasc Med       Date:  2021-12-14

Review 9.  Medical management of acute heart failure.

Authors:  Hayaan Kamran; W H Wilson Tang
Journal:  Fac Rev       Date:  2021-12-06

10.  Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.

Authors:  Joban Vaishnav; Jessica E Chasler; Yizhen J Lee; Chiadi E Ndumele; Jiun-Ruey Hu; Steven P Schulman; Stuart D Russell; Kavita Sharma
Journal:  J Am Heart Assoc       Date:  2020-07-30       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.